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1. Introduction 
From biopharmaceutical point of view, in vitro-in vivo correlation (IV-IVC) is a predictive 
mathematical treatment describing the relationship between an in vitro property of a dosage 
form (usually the rate or extent of drug release) and a relevant in vivo response (e.g. plasma 
or urine drug concentrations or amount of drug absorbed). IV-IVC is recommended by 
various regulatory bodies and mostly applicable to drug dosage forms for oral routes and 
sustained release products. It is a useful tool for drug dosage form development, because a 
successful correlation can assist in the selection of drug formulation with appropriate and 
acceptable dissolution criteria, and depending on its predictiveness, it can be used as a 
forecast or surrogate for further bioequivalence studies. There are different categories of IV-
IVC; A, B, C and D. 
In biopharmaceutics classification system (BCS), aspirin belong to class 2, and because of its 
poor water solubility, the dissolution rate is the rate limiting step, which controls the 
absorption and bioavailability parameters of oral aspirin drug products. This criterion 
makes aspirin a good candidate for IV-IVC evaluation. In vitro–in vivo correlation of four 
commercial brands of aspirin tablets (one soluble brand and three regular brands) marketed 
in Nigeria are presented. USPXXI rotating basket apparatus and urinary excretion profiles 
from eight human volunteers were employed for in vitro and in vivo assessments 
respectively. Various dissolution parameters such as percent dissolved in 30 min, 
dissolution rate constants (k) and time for 50 % dissolution (DT50%) and pharmacokinetic 
parameters such as cumulative amount excreted up to 8 h (E8), maximum excretion rate 
(dE/dt)max and time for maximum excretion rate (Tmax) were obtained for all the brands.  
The soluble aspirin had the highest percent dissolved in 30 minutes and highest dissolution 
rate constant with shortest time for 50% dissolution compared with other regular aspirin 
brands. Comparatively, the soluble aspirin had the highest E8 and highest (dE/dt)max with 
the shortest Tmax. Significant rank order correlations were observed between all the in vitro 
dissolution parameters such as percent dissolved at 30 min, dissolution rate constants (k) 
and time for 50 % dissolution (DT50%) and all the in vivo bioavailability parameters such as 
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cumulative amount excreted up to 8 h (E8), maximum excretion rate (dE/dt)max and time for 
maximum excretion rate (Tmax). However, no correlation could be established between the 
cumulative amount excreted up to 24 h (E24) and any of the in vitro dissolution parameters. 
Moreover statistical analysis showed no significant inter-subject variation among the human 
subjects that participated in the experiments.  
Soluble aspirin tablet exhibited a higher in vitro dissolution and in vivo bioavailability 
profiles than regular aspirin tablets. The three regular aspirin brands were not bioequivalent 
to the soluble brands of aspirin. Good IV-IVC was established for the four brands of aspirin 
tablets. Therefore, with proper standardization of methods of assessment, in vitro 
dissolution parameters can be used to predict in vivo bioavailability of these aspirin tablets 
marketed in Nigeria. 
1.1 Quality assessment of drug products  
1.1.1 In vitro quality assessment of drug products 
The quality of drug product especially oral solid dosage forms such as tablets and capsules 
are often assessed by carrying out certain in vitro tests as contained in the monographs of 
various pharmacopoeias. Such test include: assay of active ingredients; weight uniformity; 
content uniformity; hardness; friability; disintegration and dissolution tests. These are to 
ensure batch to batch uniformity of quality during manufacturing processes. 
The general assumption was that if the physical and chemical integrity of a drug product 
were assured, satisfactory pharmacologic or therapeutic performance would be obtained 1, 2 
1.1.2 In vivo quality assessment of drug products   
In addition to the vitro quality assessment of drug products as prescribed in various 
pharmacopeias, in vivo bioavailability requirement is now an essential parameter in quality 
control of a number of medicinal products, particularly, those which have low or high 
therapeutic index or those which are poorly water soluble.  This became necessary in view of 
apparent inadequacy of the in vitro pharmacopoeia tests which did not take into consideration 
whether or not the active ingredient would be released from the dosage form, nor at what rate 
it gets into the biologic system.3 Many formulations were produced and marketed that 
satisfied all the required legal standards but which were not therapeutically active.4  
Events and certain realizations have revealed that percentage chemical strength was not the 
sole criterion for clinical effectiveness. It became obvious that a dosage form must not only 
contain the correct amount of labeled drugs, but must also release the drugs on 
administration for absorption in the patient. So apart from chemical purity and percentage 
strength, bioavailability, clinical efficacy and safety became additional criteria for effective 
product development.5 It is now recognized that various physicochemical properties and 
formulation factors can influence the biologic availability of medicaments from dosage from 
in the body system.1     
1.2 Rate limiting step in drug bioavailability  
Systemic absorption of most drug products consists of a succession of rate processes. These 
processes include: (i) disintegration of the drug product and subsequent release of the drug; 
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(ii) dissolution of the drug in an aqueous environment: and (iii) absorption across cell 
membrane into the systemic circulation. In the process of drug disintegration, dissolution 
and absorption, the rate at which drug reaches the circulatory system is determined by the 
slowest step in the sequence. 
The slowest step in a series of kinetic process is called the rate-limiting step, except for 
sustained release or prolonged-action products; disintegration of a solid drug product is 
usually more rapid than dissolution and drug absorption. For drugs that have very poor 
aqueous solubility for example aspirin, the rate at which the drug dissolves (dissolution) is 
often the slowest step, and therefore, exerts a rate-limiting effect on drug bioavailability. In 
contrast, for a drug that has a high aqueous solubility, the dissolution rate is rapid and the 
rate at which the drug crosses or permeates cell membranes (absorption) is the slowest or 
rate limiting step 3, 5 
1.3 In vivo dissolution and drug bioavailability  
In biologic systems, drug dissolution in an aqueous medium is an important condition for 
systemic absorption and subsequent bioavailability. The rate at which drug with poor 
aqueous solubility dissolve from an intact or disintegrated solid dosage form in the gastro 
intestinal tract often controls the rate of systemic absorption of the drug. 
Dissolution is the process by which a drug substance is released from the dosage from into a 
dissolution medium. A drug administered in a tablet or capsule form must be released, 
dissolved and reach its site of action before it can exert a pharmacological response. 
Dissolution of drug in the body represents the end of the release process and precedes the 
absorption of drugs from solid dosage forms. Various theories of tablet dissolution that have 
been proffered include: (i) the diffusion layer model, (ii) the Noyes-Whitney theory, (iii) the 
Wagner’s, (iv) the Kitazawa, (v) the El-Yazigi, (vi) the Carstensen’s theories, (vii) the 
Danckwert’s model 5  
Dissolution kinetics of a drug product can be influenced by various factors such as (i) the 
physicochemical characteristics of the drug substance e.g. particle size, particle shape, 
polymorphism, crystal form, salt ester formation; (ii) formulation factors such as the nature 
and amount of excipients e.g. diluents, disintegrants, binders, lubricants, etc. (iii) 
manufacturing procedures such as the method of granulation, the size and density of the 
granules, moisture content, age of the granules, compressional force used in tabletting 
process, the quality of the personnel, the sophistication of the equipment and level of in-
process quality control 4, 5 
Drug in the body particularly, in the gastrointestinal tract, is considered to be dissolving in 
an aqueous environment. Therefore, temperature of the medium and the agitation rate also 
affect the rate drug dissolution. The in vivo temperature is maintained at a constant 
temperature of 37oc, and the agitation (primarily peristaltic movement in the gastro- 
intestinal tract) is reasonably constant 2, 3, 5  
1.4 In vitro dissolution tests  
Dissolution test is an in vitro physicochemical testing of solid oral dosage form. It 
determines the amount of active ingredient(s) released from a solid oral dosage from, 
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such as from tablets or capsules, using a know volume of dissolution medium, with a 
predetermined length of time. The general principle of dissolution test is that the solid 
dosage form is tested under uniform agitation in an attempt to achieve dissolution. 
Agitation is accomplished by either using stirrer inside the apparatus or rotating the 
container holding the dosage form. In vitro dissolution test can be used to guide 
formulation development, identify critical manufacturing variables, monitor formulation 
quality from batch to batch, predict in vitro performance, monitor manufacturing process, 
assure batch to batch product performance and serve as a surrogate for bioavailability and 
bioequivalence.  
The choice of dissolution apparatus varies from one drug to another, depending on the 
nature of the drug. Conditions employed for the in vitro dissolution test are made in such a 
way to give the best and reproducible results for the particular drug under test. Such 
conditions include the size and shape of the dissolution vessel, the agitation rate, 
temperature of the dissolution medium which for most dissolution test is temperature of 
37oc which is similar to the in vivo temperature. The nature and volume of the dissolution 
media is also important e.g. simulated gastric fluid, simulated intestinal fluid, water, 0.1N 
Hcl, phosphate and acetate buffer depending on the nature of the drug and the location in 
the gastro-intestinal tract where the drug is expected to dissolve. The volume of the 
dissolution medium ranges from 500ml to 1000ml. 6, 7, 5  
There are several official methods of carrying out dissolution test of tablets and capsules e.g. 
rotating basket method (Apparatus 1); paddle method (Apparatus 2); transdermal product 
testing (Apparatus 3) transdermal product testing (Apparatus 4); transdermal product 
testing (Apparatus 5).2 Other unofficial methods are rotating bottle method; flow-through 
dissolution method; intrinsic dissolution method, and peristalsis method.8 
1.5 Bioavailability assessment 
Bioavailability of a drug refers to the measurement of the rate and extent of active drug that 
reaches the systemic circulation. The in vivo behaviours of a dosage form can be explained 
more precisely by its bioavailability. Bioavailability studies are carried out for both 
approved drugs and those not yet approved for marketing by drug regulatory agencies. 
This is to ensure that such drugs are safe and effective for their labeled indications for use 
and that they meet all applicable standards of identity, strength, quality and purity. In vivo 
bioavailability assessments are also performed for new formulations of active drug 
ingredients or therapeutic moieties that have full new drug application approvals. Various 
factors affecting the dissolution of a drug will invariable affect its bioavailability e.g. the 
physicochemical properties of the drug, formulation factors and manufacturing processes.9, 5  
1.6 Methods of assessing bioavailability 
There are several direct and indirect methods of assessing bioavailability in humans. The 
selection of a method depends on the purpose of the study, analytical method of drug 
measurement, and nature of the drug product. The methods are namely: 
i. Pharmacokinetic method: this is the measurement of the active drug substance or its 
metabolite(s) in biological fluids such as blood, plasma, urine, saliva, bile, sweat, milk, 
breath, feaces and other tissues. 
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ii. Acute pharmacologic effect. An acute pharmacologic effect such as effect on pupil 
diameter, heart rate or blood pressure can be useful as an index of drug bioavailability. 
This may require demonstration of dose related responses.    
iii. Clinical observation: such as lack of response (therapeutic failure) good response or 
toxicity in patience receiving similar drug products may be used to determine drug 
bioavailability. 
iv. iv. In-vitro dissolution test: this is done in selected case where in vitro / in vivo 
correction has been established for such drug product. 
Because the free or therapeutically active drug can be accurately quantified in biological 
fluids, pharmacokinetic method is often preferred. Among all the body fluids, plasma and 
urine data gives the most objective information on bioavailability while the rest are less 
reliable. 
The urine method of assessment has some advantages over the blood: 
i. Samples are more easily obtained than blood, 
ii. Urine collection is more pleasant to the subjects and more convenient, 
iii. The concentration of the drugs in the urine is often higher than in the blood, so, simple 
analytical method (e.g. U.V. spectrophotometer) can be used,  
iv. Lack of protein in the urine of a healthy individual obviates the need for denaturation 
step. 
However, the following conditions are necessary for obtaining valid urinary excretion data.  
i. Frequent sampling is necessary for a good curve description. 
ii. Urine sample should be collected periodically until almost the entire drug has been 
excreted (a period of approximately seven elimination half lives) 
iii. Urinary pH must be kept constant to avoid significant variation in urinary excretion 
rate. 
iv. Subject participating in the study should submit a complete urine specimen i.e. 
completely emptying the bladder.10, 1, 11, 2, 5  
1.7 Pharmacokinetic parameters for bioavailability assessment  
There are various pharmacokinetic parameters usually employed in evaluating 
bioavailability when drugs are assessed in biological fluids. 
Plasma:  
i. AUC- area under the plasma level-time curve and it reflects the total amount of active 
drug reaching the systemic circulation. 
ii.  Cmax - is the maximum plasma drug concentration obtained after administration of 
drug. 
iii. Tmax – time of maximum plasma concentration, it corresponds to the time required to 
reach maximum drug concentration. At Tmax, rate of absorption equals rate of 
elimination. Absorption continues after Tmax but at a slower rate.  
Urine: 
i. [E]∞ - Cumulative amount of drug excreted in the urine over a sufficient period of time 
(usually above 7 half-lives). It is directly related to the total amount of drug absorbed  
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ii. [dE/dt]max –Maximum rate of drug excretion, is the maximum rate at which drug is 
excreted in the urine after the administration of the drug.  
iii. Tmax - Time of maximum urinary excretion rate, it is the time required to reach 
maximum rate of drug excretion after drug administration. 
The AUC and [E]∞   are similar in the sense that they both measure the extend of drug 
absorption (bioavailability) while Tmax  indicate the rate of drug absorption. Cmax and 
[dE/dt]max are analogous in the sense that they reflect both the rate and extent of absorption. 
If the rate of drug excretion in urine is proportional to the concentration in blood, the curve 
obtained by plotting [dE/dt] against time will be the same as the plasma concentration-time 
curve, and Tmax will be the same. 12, 4, 2, 13, 3, 5 
1.8 In vitro – in vivo correlation of aspirin tablets 
The formulation and implementation of regulations concerning bioavailability of drugs 
made considerable attention to be given to correlation of in vitro dissolution rate with in 
vivo bioavailability14. It has been observed that with proper attention to the operating 
conditions, dissolution test can become a valuable indicator for potential in-vivo 
performance. In vitro-in vivo correlation (IV-IVC) is a predictive mathematical treatment 
describing the relationship between an in vitro property of a dosage form (usually the rate 
or extent of drug release) and a relevant in vivo response (e.g. plasma drug concentrations 
or amount of drug absorbed). Establishing an IV-IVC needs an extensive study of drug 
release from an oral drug delivery system. The study of drug in vitro availability and 
bioavailability are important part of the IV-IVC procedure for suitable drugs.15 In order to 
develop safe and effective drugs and validate their formulation, it is important to identify 
the exact drug pharmacokinetic parameters and biopharmaceutical properties of the 
dosage forms.  
The main objective of establishing IV-IVC is to use dissolution test as a surrogate for in vivo 
bioavailability studies and reduce the need for expensive human studies.16, 17 When in vitro-
in vivo correlations are established on a formulation, dissolution specifications can be used 
as a means of controlling drug bioavailability and hence a substitute for human 
bioequivalence studies.5 There are different categories of IV-IVC; A, B, C and D. Level A 
correlation represents a point-to-point relationship between in vitro dissolution rate and in 
vivo input rate of drug from the dosage form. 
Level B correlation utilizes the principle of statistical moment analysis, where the mean in 
vitro dissolution time (MDTvitro) of the product is compared to either mean in vivo resident 
time (MRT) or the mean in vivo dissolution time (MDTvivo). Level C correlation, compares 
one or several dissolution time points (t50%, t90%, etc.) to  one or several mean 
pharmacokinetic parameter such as AUC, tmax, or Cmax, 
Level D correlation is a rank order and qualitative analysis and is not considered useful for 
regulatory purposes. It is not a formal correlation but serves as an aid in the development of 
a formulation or processing procedure.14 
In the last few years aspirin has become a life saver against cardiovascular complications in 
addition to its age long usefulness as an analgesic, antipyretic and anti-inflammatory agent. 
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Aspirin is rapidly absorbed by first order kinetics, following oral administration but is 
subjected to extensive metabolism to form salicylates which is rapidly and extensively 
distributed throughout body fluids. The salicylate level in the urine rapidly increases and 
can be easily detected and analyzed through colorimetric method.18,19,20,11 In 
biopharmaceutics classification system (BCS), aspirin belong to class 2 (drug with low 
solubility but high permeability). Therefore, because, of its poor water solubility, the 
dissolution rate is the rate limiting step, which controls the absorption and bioavailability 
parameters of oral aspirin drug products. This criterion makes aspirin a good candidate for 
IV-IVC study, because any physico-chemical and formulation factors influencing its in vitro 
dissolution profile is expected to affect its in vivo bioavailability. In vitro–in vivo correlation 
of four commercial brands of aspirin tablets (one soluble brand and three regular brands) 
marketed in Nigeria are presented21, 22. Good correlations between various dissolution and 
bioavailability parameters of some drugs have been documented12, 23, 24, 25, 26, 27. However, in 
some cases, no good correlation could be obtained as reported by some investigators28, 29, 30. 
The following investigations were conducted:   
a. In vitro dissolution profiles  
In vitro dissolution profiles of the four brands of aspirin were evaluated, using USPXXI 
rotating basket apparatus. The dissolution profiles expressed as percents aspirin dissolved 
as a function of time for all the brands are shown in Figure 1. Various dissolution 
parameters such as percent dissolved in 30 min, dissolution rate constants (k) and time for 
50% dissolution (DT50%) were obtained for all the brands using standard methods 2. These 
are presented in Table 1.  
 
 
Brand 
Percent dissolved at  
30 min 
Dissolution rate 
constant,  
k (hr-1) 
Time for 50% 
dissolution,  
dt50% (min) 
A1 75.71 0.059 11.79 
A2 65.75 0.040 17.41 
A3 63.47 0.037 18.53 
A4 68.90 0.043 16.23 
Table 1. Dissolution parameters obtained from the dissolution tests of the various brands of 
aspirin tablets 
Figure 1 shows that A1 exhibited the highest dissolution rate while the other three brands 
(A2 - A4) has similar dissolution rates (p <0.05). Table 1 shows that overall relative ranking 
of all the brands in terms of  the percent dissolved in 30 min and dissolution rate constant 
(k) followed the order of A1>A4>A2>A3 while the ranking of time for 50% dissolution 
(DT50%)  follows the reverse order (i.e. A1<A4<A2<A3). A1 is a soluble brand of aspirin 
containing calcium carbonate which can provide a reactive medium by changing the pH of 
the environment adjacent to the drug to alkaline, thus making the acidic drug like aspirin 
form a water soluble salt, thereby enhancing its rapid dissolution. This possibly accounted 
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for its highest solubility rate and shortest time for dissolution compared with the other plain 
brands31. Brands A2, A3 and A4 are all plain aspirin tablets; various factors such as particle 
size and shape of the aspirin content, type and/or amount of excipients, method of 
formulation and compression force employed may influence their dissolution rates 32, 5 The 
analysis of variance (ANOVA) performed on the percent dissolved in 30 min shows no 
significant difference (P>0.05) among all the brands, they all indicated similar statistical 
behaviors in their in vitro dissolution profiles.  
 
Fig. 1. Percent of actual amount of aspirin dissolved as a function of time for the four 
different brands. 
b. In vivo bioavailability 
In vivo bioavailability of the same set of aspirin tablets were assessed in eight human 
volunteers using urinary excretion profiles and various in vivo pharmacokinetic parameters 
such as cumulative amount excreted up to 8 h (E8), maximum excretion rate (dE/dt)max and 
time for maximum excretion rate (Tmax) were calculated using standard methods30 and are 
presented in Table 2. The cumulative salicylate excreted and excretion rate profiles of the 
soluble aspirin and the three plain aspirin tablets are presented in figure 2 and 3 
respectively. Pharmacokinetic parameters determined were cumulative amount excreted up 
to 8h (E8) and 24h (E24), maximum excretion rate (dE/dt)max  and time for maximum 
excretion rate (Tmax) 
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Brand 
Cumulative 
amount excreted 
up to 8h (E8) 
Cumulative amount 
excreted up to 24 h 
(E24) 
Maximum 
excretion rate 
(dE/dt)max 
Time for maximum 
excretion rate 
(Tmax) 
A1 173.49 290.59 32.76 2.50 
A2 165.15 275.68 29.93 3.38 
A3 164.36 247.63 29.64 3.50 
A4 169.79 281.10 31.36 3.13 
Table 2. Pharmacokinetic parameters obtained from urinary excretion analysis of various 
brands of aspirin.  
 
Fig. 2. Cumulative amount of salicylate excreted up to 24 h for the different brands of Aspirin. 
The analysis of variance (ANOVA) performed on the pharmacokinetic parameters shows 
that all the four brands are bioequivalent in terms of (E8), (E24) and (dE/dt)max, but the Tmax 
of the three plain brands are inequivalent to the soluble brand A1 which has the fastest time 
for maximum excretion rate. Figure 3 shows that graphs for A2, A3 and A4 were almost 
super imposable attesting further to their equivalence. The formulation factors that 
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enhanced the in vitro dissolution of the soluble aspirin are possibly responsible for increase 
in its in vivo bioavailability, compared to other plain brands, since its dissolution process is 
the rate limiting step 14, 29. 
 
 
Fig. 3. Excretion rate profiles of the four different brands of Aspirin. 
c. In vitro-in vivo correlation (IV- IVC)  
To establish the relevance of the in vitro dissolution performances to the in vivo 
pharmacokinetic parameters of the four aspirin brands, level C IV-IVC was employed. 
When various dissolution parameters were correlated with various bioavailability 
parameters, no significant IV-IVC could be established using E24 value. However, significant 
IV-IVC was observed when cumulative amount excreted up to 8 hours (E8)  
was employed (Figure 4) with correlation coefficients r2 > 0.8. As shown in Figure 4, good 
quantitative correlation coefficients were observed between percent dissolved in 30 min 
and: (a) cumulative amount excreted up to 8 hours (E8) (r2 = 0.9532, p < 0.05),  
(b) Maximum excretion rate (dE/dt)max, r2 = 0.9697, p < 0.05) and (c) Time for maximum 
excretion rate (Tmax) (r2 = 0.9932, p < 0.05), thus the in vitro parameter correlated well  
with the in vivo parameters. Similarly, from Figure 5, good quantitative correlation 
coefficients were also observed between dissolution rate constant (k) and Tmax (r2 = 0.9813,  
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p < 0.05). With regards to E8 and (dE/dt)max, the correlation was not as perfect as that of 
Tmax, with correlation coefficients just above 0.8, with exact values of 0.8564 and 0.8879 
respectively.  
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Fig. 4. Correlation of in vitro dissolution parameter (percent dissolved in 30 min) with 
various in vivo bioavailability parameters. 
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Fig. 5. Correlation of in vitro dissolution rate constant with various in vivo bioavailability 
parameters. 
Finally, Figure 6 equally shows that good quantitative correlations were established 
between time for 50% dissolution (DT50%) and (a) E8 (r2 = 0.9041, p < 0.05), (b) (dE/dt) max  
(r2 = 0.9297, p < 0.05) and (c) Tmax (r2 = 0.9954, p < 0.05) 
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Fig. 6. Correlation of time for 50 % in vitro dissolution with various in vivo bioavailability 
parameters. 
In all the IV-IVC performed, best correlation was obtained between the in vivo parameter 
Tmax, and all the in vitro parameters used for the correlation. The correlation coefficient 
recorded in each case was higher than others. The significant IV-IVC observed were in 
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agreement with the observations of some workers 12, 25 who carried out their own studies on 
aspirin in centers outside Nigeria. 
2. Summary  
Using USPXXI rotating basket dissolution apparatus, soluble brand of aspirin tablet A1 
exhibited the highest dissolution profile, when compared to other plain brands of aspirin 
ANOVA of pharmacokinetic data obtained from colorimetric assay of urinary salicylate 
excretion of the four brands of aspirin showed that all the four brands are bioequivalent in 
terms of (E8), (E24) and (dE/dt)max , but  the Tmax of the three plain brands are not equivalent 
to the soluble brand A1 which has the fastest time for maximum excretion rate. 
Good in vitro-in vivo correlations were established between various dissolution and 
bioavailability parameters of four commercial brands of aspirin tablets using Level C in 
vitro-in vivo correlation approach. Therefore, with proper standardization of methods of 
assessment, in vitro dissolution parameters can be used to predict in vivo bioavailability of 
these aspirin tablets marketed in Nigeria. 
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